ROYALTY PHARMA PLC- CL A (RPRX) Fundamental Analysis & Valuation

NASDAQ:RPRX • GB00BMVP7Y09

Current stock price

45.61 USD
+0.25 (+0.55%)
At close:
45.61 USD
0 (0%)
After Hours:

This RPRX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. RPRX Profitability Analysis

1.1 Basic Checks

  • RPRX had positive earnings in the past year.
  • In the past year RPRX had a positive cash flow from operations.
  • In the past 5 years RPRX has always been profitable.
  • In the past 5 years RPRX always reported a positive cash flow from operatings.
RPRX Yearly Net Income VS EBIT VS OCF VS FCFRPRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B

1.2 Ratios

  • RPRX has a Return On Assets of 3.93%. This is amongst the best in the industry. RPRX outperforms 84.97% of its industry peers.
  • RPRX has a Return On Equity of 11.90%. This is amongst the best in the industry. RPRX outperforms 86.01% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 6.49%, RPRX belongs to the top of the industry, outperforming 83.42% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for RPRX is significantly below the industry average of 13.06%.
Industry RankSector Rank
ROA 3.93%
ROE 11.9%
ROIC 6.49%
ROA(3y)5.19%
ROA(5y)3.87%
ROE(3y)13.89%
ROE(5y)10.63%
ROIC(3y)6.59%
ROIC(5y)6.19%
RPRX Yearly ROA, ROE, ROICRPRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30

1.3 Margins

  • RPRX has a Profit Margin of 32.42%. This is amongst the best in the industry. RPRX outperforms 95.34% of its industry peers.
  • RPRX's Profit Margin has improved in the last couple of years.
  • RPRX's Operating Margin of 65.58% is amongst the best of the industry. RPRX outperforms 100.00% of its industry peers.
  • RPRX's Operating Margin has declined in the last couple of years.
Industry RankSector Rank
OM 65.58%
PM (TTM) 32.42%
GM N/A
OM growth 3Y16.71%
OM growth 5Y-3.47%
PM growth 3Y156.85%
PM growth 5Y6.8%
GM growth 3YN/A
GM growth 5YN/A
RPRX Yearly Profit, Operating, Gross MarginsRPRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025 50 100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. RPRX Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so RPRX is destroying value.
  • The number of shares outstanding for RPRX has been reduced compared to 1 year ago.
  • RPRX has more shares outstanding than it did 5 years ago.
  • RPRX has a worse debt/assets ratio than last year.
RPRX Yearly Shares OutstandingRPRX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M
RPRX Yearly Total Debt VS Total AssetsRPRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

2.2 Solvency

  • Based on the Altman-Z score of 1.80, we must say that RPRX is in the distress zone and has some risk of bankruptcy.
  • RPRX's Altman-Z score of 1.80 is fine compared to the rest of the industry. RPRX outperforms 62.69% of its industry peers.
  • The Debt to FCF ratio of RPRX is 11.30, which is on the high side as it means it would take RPRX, 11.30 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of RPRX (11.30) is better than 78.76% of its industry peers.
  • RPRX has a Debt/Equity ratio of 1.32. This is a high value indicating a heavy dependency on external financing.
  • RPRX has a worse Debt to Equity ratio (1.32) than 73.58% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.32
Debt/FCF 11.3
Altman-Z 1.8
ROIC/WACC0.74
WACC8.82%
RPRX Yearly LT Debt VS Equity VS FCFRPRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2B 4B 6B 8B

2.3 Liquidity

  • RPRX has a Current Ratio of 2.40. This indicates that RPRX is financially healthy and has no problem in meeting its short term obligations.
  • RPRX's Current ratio of 2.40 is in line compared to the rest of the industry. RPRX outperforms 46.11% of its industry peers.
  • RPRX has a Quick Ratio of 2.40. This indicates that RPRX is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 2.40, RPRX is in line with its industry, outperforming 51.81% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.4
Quick Ratio 2.4
RPRX Yearly Current Assets VS Current LiabilitesRPRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. RPRX Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 8.05% over the past year.
  • RPRX shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 0.60% yearly.
  • Looking at the last year, RPRX shows a small growth in Revenue. The Revenue has grown by 5.06% in the last year.
  • RPRX shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.30% yearly.
EPS 1Y (TTM)8.05%
EPS 3Y6.47%
EPS 5Y0.6%
EPS Q2Q%27.83%
Revenue 1Y (TTM)5.06%
Revenue growth 3Y2.06%
Revenue growth 5Y2.3%
Sales Q2Q%4.71%

3.2 Future

  • Based on estimates for the next years, RPRX will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.16% on average per year.
  • RPRX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.01% yearly.
EPS Next Y16.65%
EPS Next 2Y11.8%
EPS Next 3Y11.89%
EPS Next 5Y12.16%
Revenue Next Year4.05%
Revenue Next 2Y4.43%
Revenue Next 3Y5.93%
Revenue Next 5Y10.01%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
RPRX Yearly Revenue VS EstimatesRPRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 1B 2B 3B 4B 5B
RPRX Yearly EPS VS EstimatesRPRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2 4 6 8

More info and screens

Find the best growth stocksShow best growing peers

7

4. RPRX Valuation Analysis

4.1 Price/Earnings Ratio

  • RPRX is valuated reasonably with a Price/Earnings ratio of 10.30.
  • Based on the Price/Earnings ratio, RPRX is valued cheaper than 89.12% of the companies in the same industry.
  • RPRX's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 25.54.
  • Based on the Price/Forward Earnings ratio of 8.83, the valuation of RPRX can be described as reasonable.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of RPRX indicates a rather cheap valuation: RPRX is cheaper than 90.16% of the companies listed in the same industry.
  • When comparing the Price/Forward Earnings ratio of RPRX to the average of the S&P500 Index (22.70), we can say RPRX is valued rather cheaply.
Industry RankSector Rank
PE 10.3
Fwd PE 8.83
RPRX Price Earnings VS Forward Price EarningsRPRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • RPRX's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. RPRX is cheaper than 79.79% of the companies in the same industry.
Industry RankSector Rank
P/FCF 33.22
EV/EBITDA N/A
RPRX Per share dataRPRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of RPRX may justify a higher PE ratio.
PEG (NY)0.62
PEG (5Y)17.19
EPS Next 2Y11.8%
EPS Next 3Y11.89%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. RPRX Dividend Analysis

5.1 Amount

  • RPRX has a Yearly Dividend Yield of 2.06%. Purely for dividend investing, there may be better candidates out there.
  • Compared to an average industry Dividend Yield of 0.79, RPRX pays a better dividend. On top of this RPRX pays more dividend than 92.75% of the companies listed in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.89, RPRX has a dividend comparable with the average S&P500 company.
Industry RankSector Rank
Dividend Yield 2.06%

5.2 History

  • RPRX has been paying a dividend for over 5 years, so it has already some track record.
  • RPRX has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)N/A
Div Incr Years4
Div Non Decr Years4
RPRX Yearly Dividends per shareRPRX Yearly Dividends per shareYearly Dividends per share 2020 2021 2022 2023 2024 2025 2026 0.2 0.4 0.6 0.8

5.3 Sustainability

  • 49.06% of the earnings are spent on dividend by RPRX. This is a bit on the high side, but may be sustainable.
DP49.06%
EPS Next 2Y11.8%
EPS Next 3Y11.89%
RPRX Yearly Income VS Free CF VS DividendRPRX Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B
RPRX Dividend Payout.RPRX Dividend Payout, showing the Payout Ratio.RPRX Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

RPRX Fundamentals: All Metrics, Ratios and Statistics

ROYALTY PHARMA PLC- CL A

NASDAQ:RPRX (3/23/2026, 8:17:26 PM)

After market: 45.61 0 (0%)

45.61

+0.25 (+0.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-11
Earnings (Next)05-06
Inst Owners87.31%
Inst Owner Change7.31%
Ins Owners1.59%
Ins Owner Change8.14%
Market Cap26.31B
Revenue(TTM)2.38B
Net Income(TTM)770.95M
Analysts83.75
Price Target52.39 (14.87%)
Short Float %3.08%
Short Ratio3.27
Dividend
Industry RankSector Rank
Dividend Yield 2.06%
Yearly Dividend0.65
Dividend Growth(5Y)N/A
DP49.06%
Div Incr Years4
Div Non Decr Years4
Ex-Date02-20
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.34%
Min EPS beat(2)8.69%
Max EPS beat(2)9.99%
EPS beat(4)3
Avg EPS beat(4)-9.55%
Min EPS beat(4)-59.9%
Max EPS beat(4)9.99%
EPS beat(8)5
Avg EPS beat(8)-3.66%
EPS beat(12)9
Avg EPS beat(12)0.82%
EPS beat(16)10
Avg EPS beat(16)-0.51%
Revenue beat(2)1
Avg Revenue beat(2)-7.72%
Min Revenue beat(2)-23.38%
Max Revenue beat(2)7.95%
Revenue beat(4)3
Avg Revenue beat(4)-0.41%
Min Revenue beat(4)-23.38%
Max Revenue beat(4)9.61%
Revenue beat(8)3
Avg Revenue beat(8)-7.18%
Revenue beat(12)3
Avg Revenue beat(12)-9.25%
Revenue beat(16)3
Avg Revenue beat(16)-10.51%
PT rev (1m)7.86%
PT rev (3m)13.89%
EPS NQ rev (1m)0.55%
EPS NQ rev (3m)5.22%
EPS NY rev (1m)-0.37%
EPS NY rev (3m)-0.36%
Revenue NQ rev (1m)0.76%
Revenue NQ rev (3m)93.91%
Revenue NY rev (1m)-0.57%
Revenue NY rev (3m)4.41%
Valuation
Industry RankSector Rank
PE 10.3
Fwd PE 8.83
P/S 11.06
P/FCF 33.22
P/OCF 10.57
P/B 4.06
P/tB 4.74
EV/EBITDA N/A
EPS(TTM)4.43
EY9.71%
EPS(NY)5.17
Fwd EY11.33%
FCF(TTM)1.37
FCFY3.01%
OCF(TTM)4.32
OCFY9.46%
SpS4.12
BVpS11.23
TBVpS9.62
PEG (NY)0.62
PEG (5Y)17.19
Graham Number33.45
Profitability
Industry RankSector Rank
ROA 3.93%
ROE 11.9%
ROCE 8.21%
ROIC 6.49%
ROICexc 7.04%
ROICexgc 7.44%
OM 65.58%
PM (TTM) 32.42%
GM N/A
FCFM 33.31%
ROA(3y)5.19%
ROA(5y)3.87%
ROE(3y)13.89%
ROE(5y)10.63%
ROIC(3y)6.59%
ROIC(5y)6.19%
ROICexc(3y)7.21%
ROICexc(5y)6.98%
ROICexgc(3y)7.34%
ROICexgc(5y)7.06%
ROCE(3y)8.34%
ROCE(5y)7.84%
ROICexgc growth 3Y10.47%
ROICexgc growth 5Y-5.87%
ROICexc growth 3Y8.49%
ROICexc growth 5Y-6.85%
OM growth 3Y16.71%
OM growth 5Y-3.47%
PM growth 3Y156.85%
PM growth 5Y6.8%
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 1.32
Debt/FCF 11.3
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 71.39%
Interest Coverage -5.64
Cash Conversion N/A
Profit Quality 102.74%
Current Ratio 2.4
Quick Ratio 2.4
Altman-Z 1.8
F-Score5
WACC8.82%
ROIC/WACC0.74
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)90.64%
Cap/Sales(5y)89.1%
Profit Quality(3y)70.09%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.05%
EPS 3Y6.47%
EPS 5Y0.6%
EPS Q2Q%27.83%
EPS Next Y16.65%
EPS Next 2Y11.8%
EPS Next 3Y11.89%
EPS Next 5Y12.16%
Revenue 1Y (TTM)5.06%
Revenue growth 3Y2.06%
Revenue growth 5Y2.3%
Sales Q2Q%4.71%
Revenue Next Year4.05%
Revenue Next 2Y4.43%
Revenue Next 3Y5.93%
Revenue Next 5Y10.01%
EBIT growth 1Y20.66%
EBIT growth 3Y19.11%
EBIT growth 5Y-1.25%
EBIT Next Year13.04%
EBIT Next 3Y10.82%
EBIT Next 5Y10.98%
FCF growth 1Y200.85%
FCF growth 3Y25.33%
FCF growth 5YN/A
OCF growth 1Y-10.08%
OCF growth 3Y5.11%
OCF growth 5Y4.12%

ROYALTY PHARMA PLC- CL A / RPRX Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ROYALTY PHARMA PLC- CL A?

ChartMill assigns a fundamental rating of 6 / 10 to RPRX.


What is the valuation status for RPRX stock?

ChartMill assigns a valuation rating of 7 / 10 to ROYALTY PHARMA PLC- CL A (RPRX). This can be considered as Undervalued.


How profitable is ROYALTY PHARMA PLC- CL A (RPRX) stock?

ROYALTY PHARMA PLC- CL A (RPRX) has a profitability rating of 7 / 10.


Can you provide the PE and PB ratios for RPRX stock?

The Price/Earnings (PE) ratio for ROYALTY PHARMA PLC- CL A (RPRX) is 10.3 and the Price/Book (PB) ratio is 4.06.


Can you provide the dividend sustainability for RPRX stock?

The dividend rating of ROYALTY PHARMA PLC- CL A (RPRX) is 4 / 10 and the dividend payout ratio is 49.06%.